Brief: Eledon Pharmaceuticals Announces 12Th Participant Enrolled In Phase 2 Bestow Trial Evaluating Tegoprubart For The Prevention Of Organ Rejection
25/03/2024 21:55
March 25 (Reuters) - Eledon Pharmaceuticals Inc
ELDN.O :
* ELEDON PHARMACEUTICALS ANNOUNCES 12TH PARTICIPANT ENROLLED
IN
PHASE 2 BESTOW TRIAL EVALUATING TEGOPRUBART FOR THE PREVENTION
OF ORGAN REJECTION
Source text for Eikon: ID:nGNX8rkTcC
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial